Diastolic dysfunction in Alzheimer’s disease model mice is associated with Aβ-amyloid aggregate formation and mitochondrial dysfunction
Open Access
- 19 July 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-19
Abstract
Alzheimer's Disease (AD) is a progressive neurodegenerative disease caused by the deposition of Aβ aggregates or neurofibrillary tangles. AD patients are primarily diagnosed with the concurrent development of several cardiovascular dysfunctions. While few studies have indicated the presence of intramyocardial Aβ aggregates, none of the studies have performed detailed analyses for pathomechanism of cardiac dysfunction in AD patients. This manuscript used aged APPSWE/PS1 Tg and littermate age-matched wildtype (Wt) mice to characterize cardiac dysfunction and analyze associated pathophysiology. Detailed assessment of cardiac functional parameters demonstrated the development of diastolic dysfunction in APPSWE/PS1 Tg hearts compared to Wt hearts. Muscle function evaluation showed functional impairment (decreased exercise tolerance and muscle strength) in APPSWE/PS1 Tg mice. Biochemical and histochemical analysis revealed Aβ aggregate accumulation in APPSWE/PS1 Tg mice myocardium. APPSWE/PS1 Tg mice hearts also demonstrated histopathological remodeling (increased collagen deposition and myocyte cross-sectional area). Additionally, APPSWE/PS1 Tg hearts showed altered mitochondrial dynamics, reduced antioxidant protein levels, and impaired mitochondrial proteostasis compared to Wt mice. APPSWE/PS1 Tg hearts also developed mitochondrial dysfunction with decreased OXPHOS and PDH protein complex expressions, altered ETC complex dynamics, decreased complex activities, and reduced mitochondrial respiration. Our results indicated that Aβ aggregates in APPSWE/PS1 Tg hearts are associated with defects in mitochondrial respiration and complex activities, which may collectively lead to cardiac diastolic dysfunction and myocardial pathological remodeling.Keywords
Funding Information
- American Heart Association (23POST1027293, 20POST35210789, 24PRE1196230)
- National Institutes of Health (R01 HL158546, R01 HL098435, HL133497, and HL141155, P20GM121307 and R01 HL149264, R01HL145753, R01HL145753-01S1, R01HL145753-03S1, and R01HL152723)
This publication has 92 references indexed in Scilit:
- 2023 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2023
- Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)Alzheimer's & Dementia, 2021
- Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicityActa Neuropathologica, 2019
- Dysregulated Metabolism of the Amyloid‐β Protein and Therapeutic Approaches in Alzheimer DiseaseJournal of Cellular Biochemistry, 2017
- Non‐Gradient Blue Native Polyacrylamide Gel ElectrophoresisCurrent Protocols in Protein Science, 2017
- Alzheimer’s disease: experimental models and realityActa Neuropathologica, 2016
- Analysis of Mitochondrial Respiratory Chain Supercomplexes Using Blue Native Polyacrylamide Gel Electrophoresis (BN‐PAGE)Current Protocols in Mouse Biology, 2016
- Morphological alterations to neurons of the amygdala and impaired fear conditioning in a transgenic mouse model of Alzheimer's diseaseThe Journal of Pathology, 2009
- Role of mitochondrial dysfunction in Alzheimer's diseaseJournal of Neuroscience Research, 2002
- Abnormalities of mitochondrial enzymes in Alzheimer diseaseJournal of Neural Transmission, 1998